STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC)
Jordi Bruix
Consultant or Advisory Role - ArQule; Bayer; Biocompatibles; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Roche
Honoraria - Bayer; Biocompatibles; Bristol-Myers Squibb; Novartis
Research Funding - ArQule; Bayer; Daiichi Sankyo
Tadatoshi Takayama
No relevant relationships to disclose
Vincenzo Mazzaferro
No relevant relationships to disclose
Gar-Yang Chau
Research Funding - Bayer
Jiamei Yang
No relevant relationships to disclose
Masatoshi Kudo
No relevant relationships to disclose
Jianqiang Cai
No relevant relationships to disclose
Ronnie Tung-Ping Poon
No relevant relationships to disclose
Kwang-Hyub Han
No relevant relationships to disclose
Won-Young Tak
No relevant relationships to disclose
Han Chu Lee
Research Funding - Bayer
Tianqiang Song
No relevant relationships to disclose
Sasan Roayaie
No relevant relationships to disclose
Luigi Bolondi
Consultant or Advisory Role - Bayer; Bristol-Myers Squibb; Sirtex Medical
Honoraria - Bayer; Bristol-Myers Squibb; Sirtex Medical
Research Funding - Bayer; Bristol-Myers Squibb
Kwan Sik Lee
No relevant relationships to disclose
Masatoshi Makuuchi
No relevant relationships to disclose
Fabricio Souza
Employment or Leadership Position - Bayer
Marie-Aude Le Berre
Employment or Leadership Position - Bayer
Gerold Meinhardt
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
Josep M. Llovet
Consultant or Advisory Role - Bayer; BioSphere Medical; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; NanoString Technologies
Honoraria - Bayer; Bristol-Myers Squibb; Lilly; NanoString Technologies
Research Funding - Bayer; Boehringer Ingelheim